Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 21, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Entity Registrant Name	Xtant Medical Holdings, Inc.
Entity Central Index Key	0001453593
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	XTNT
Entity Common Stock, Shares Outstanding		18,173,007

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 2,069,088	$ 2,578,267
Trade accounts receivable, net of allowance for doubtful accounts of $2,109,155 and $1,653,385 respectively	13,909,090	18,991,872
Current inventories, net	24,038,913	26,266,457
Prepaid and other current assets	664,581	1,149,615
Total current assets	40,681,672	48,986,211
Non-current inventories, net	717,817	971,854
Property and equipment, net	11,450,837	15,840,730
Goodwill	41,534,626	41,534,626
Intangible assets, net	32,548,102	35,940,810
Other assets	1,523,430	827,374
Total Assets	128,456,484	144,101,605
Current Liabilities:
Accounts payable	7,350,313	10,471,944
Accounts payable - related party (note 13)	344,150	640,442
Revolving line of credit	0	10,448,283
Accrued liabilities	13,425,741	8,982,187
Warrant derivative liability	196,929	333,613
Current portion of capital lease obligations	319,095	244,847
Debt, less issuance costs	65,609,693	0
Total current liabilities	87,245,921	31,121,316
Long-term Liabilities:
Capital lease obligation, less current portion	658,011	832,152
Long-term convertible debt, less issuance costs	70,781,212	68,937,247
Long-term debt, less issuance costs	0	50,284,187
Total Liabilities	158,685,144	151,174,902
Commitments and Contingencies (note 10)
Stockholders’ Deficit:
Preferred stock, $0.000001 par value; 5,000,000 shares authorized; no shares issued and Outstanding	0	0
Common stock, $0.000001 par value; 95,000,000 shares authorized; 18,173,007 shares issued and outstanding as of September 30, 2017 and 17,249,315 shares issued and outstanding as of December 31, 2016	18	17
Additional paid-in capital	86,297,517	85,461,210
Accumulated deficit	(116,526,195)	(92,534,524)
Total Stockholders’ Deficit	(30,228,660)	(7,073,297)
Total Liabilities & Stockholders’ Deficit	$ 128,456,484	$ 144,101,605

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Trade accounts receivable, allowance for doubtful accounts (in dollars)	$ 2,109,155	$ 1,653,385
Preferred stock, par value (in dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.000001	$ 0.000001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	18,173,007	17,249,315
Common Stock, shares outstanding	18,173,007	17,249,315

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue
Orthopedic product sales	$ 19,618,192	$ 22,907,717	$ 62,985,537	$ 65,025,908
Other revenue	170,891	186,423	294,375	505,971
Total Revenue	19,789,083	23,094,140	63,279,912	65,531,879
Cost of sales	8,416,239	7,114,041	23,472,107	20,749,381
Gross Profit	11,372,844	15,980,099	39,807,805	44,782,498
Operating Expenses
General and administrative	3,330,230	3,773,236	11,985,041	11,216,112
Sales and marketing	8,903,777	11,242,820	31,037,878	32,115,763
Research and development	504,227	928,930	1,842,907	2,612,402
Depreciation and amortization	1,353,997	1,265,490	4,104,565	3,690,519
Acquisition and integration related expenses	0	517,083	0	1,269,613
Separation related expenses	791,538	0	1,396,457	0
Non-cash consulting expense	(20,000)	156,129	216,581	266,721
Total Operating Expenses	14,863,769	17,883,688	50,583,429	51,171,130
Loss from Operations	(3,490,925)	(1,903,589)	(10,775,624)	(6,388,632)
Other Income (Expense)
Interest expense	(3,809,771)	(3,163,534)	(10,538,422)	(8,974,895)
Change in warrant derivative liability	(19,549)	220,409	136,684	716,738
Other income (expense)	(1,194,041)	(51,350)	(2,814,309)	(309,924)
Total Other Income (Expense)	(5,023,361)	(2,994,475)	(13,216,047)	(8,568,081)
Benefit (Provision) for Income Taxes
Net Loss from Operations	$ (8,514,286)	$ (4,898,064)	$ (23,991,671)	$ (14,956,713)
Net loss per share:
Basic	$ (0.47)	$ (0.40)	$ (1.33)	$ (1.24)
Dilutive	$ (0.47)	$ (0.40)	$ (1.33)	$ (1.24)
Shares used in the computation:
Basic	18,169,511	12,193,970	18,065,911	12,064,782
Dilutive	18,169,511	12,193,970	18,065,911	12,064,782

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net loss	$ (23,991,671)	$ (14,956,713)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,432,544	5,551,854
Non-cash interest	9,966,139	4,477,148
Loss on impairment and disposal of fixed assets	1,909,385	0
Non-cash consulting expense/stock option expense	592,888	522,987
(Gain) loss on sale of fixed assets	0	(14,149)
Provision for losses on accounts receivable and inventory	1,710,746	898,285
Change in derivative warrant liability	(136,684)	(716,738)
Changes in operating assets and liabilities:
Accounts receivable	4,135,353	(859,026)
Inventories	1,718,264	(3,958,050)
Prepaid and other assets	(211,022)	(1,482,561)
Accounts payable	(3,417,923)	3,155,962
Accrued liabilities	(896,788)	(3,813,998)
Net cash used by operating activities	(1,188,769)	(11,194,999)
Investing activities:
Purchases of property and equipment and intangible assets	(1,455,845)	(5,566,569)
Proceeds from sale of fixed assets	0	16,400
Net cash used by investing activities	(1,455,845)	(5,550,169)
Financing activities:
Proceeds from long-term debt	12,787,094	0
Payments on capital leases	(203,376)	(80,071)
Proceeds from the issuance of long-term debt	0	1,000,000
Proceeds from the issuance of convertible debt	0	2,212,718
Proceeds from revolving line of credit	0	8,353,113
Payments on revolving line of credit	(10,448,283)	0
Net proceeds from issuance of stock	0	300,000
Net cash provided by financing activities	2,135,435	11,785,760
Net change in cash and cash equivalents	(509,179)	(4,959,408)
Cash and cash equivalents at beginning of period	2,578,267	6,368,016
Cash and cash equivalents at end of period	$ 2,069,088	$ 1,408,608

Business Description and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description and Summary of Significant Accounting Policies

(1) Business Description and Summary of Significant Accounting Policies

Business Description

The accompanying condensed consolidated financial statements include the accounts of Xtant Medical Holdings, Inc. (“Xtant”), formerly known as Bacterin International Holdings, Inc., a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc. (“Xtant Medical”), a Delaware corporation, Bacterin International, Inc., (“Bacterin”) a Nevada corporation and X-Spine Systems, Inc. (“X-spine”), an Ohio corporation, (Xtant, Xtant Medical, Bacterin and X-spine are jointly referred to herein as the “Company”). All intercompany balances and transactions have been eliminated in consolidation. Xtant develops, manufactures and markets regenerative orthopedic products for domestic and international markets and fixation devices. Xtant products serve the combined specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders to promote healing following spine, cranial and foot surgeries and the development, manufacturing and sale of medical devices for use in orthopedic spinal surgeries.

The markets in which the Company competes are highly competitive and rapidly changing. Significant technological advances, changes in customer requirements, or the emergence of competitive products with new capabilities or technologies could adversely affect the Company’s operating results. The Company’s business could be harmed by a decline in demand for, or in the prices of, its products or as a result of, among other factors, any change in pricing or distribution methods, increased price competition, changes in government regulations or a failure by the Company to keep up with technological change. Further, a decline in available donors could have an adverse impact on our business.

The accompanying interim condensed consolidated financial statements of Xtant for the three and nine months ended September 30, 2017 and 2016 are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual consolidated financial statements, but in the opinion of management, include all adjustments, consisting only of normal recurring items, necessary for a fair presentation. Interim results are not necessarily indicative of results which may be achieved in the future for the full year ending December 31, 2017.

These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto which are included in Xtant’s Annual Report on Form 10-K for the year ended December 31, 2016. The accounting policies set forth in those annual consolidated financial statements are the same as the accounting policies utilized in the preparation of these condensed consolidated financial statements, except as modified for appropriate interim consolidated financial statement presentation.

Going Concern

The Company has incurred losses since its inception. The terms, conditions and amounts outstanding under the Company’s debt agreements (See Note 7, “Debt” below) raise substantial doubt about the Company’s ability to continue as a going concern. The Company has established a special committee of its board of directors to evaluate restructuring alternatives assist in related negotiations with the Company’s lenders and consider alternatives for raising new capital. The Company also is evaluating various cost-reduction and cash flow improvement measures. However, there can be no assurance that the Company will be successful in these efforts.

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

CRO Agreement

On May 8, 2017, the Company entered into an agreement (the “CRO Agreement”) with Aurora Management Partners Inc. (“Aurora”). Pursuant to the CRO Agreement, David Baker serves as Chief Restructuring Officer of the Company (the “CRO”). The CRO and Aurora personnel, referred to as Deputy Restructuring officers, assisting on this engagement report to the special restructuring committee of the board of directors of the Company and provide periodic updates on progress made in fulfilling the scope of services. The term of the agreement will continue until the engagement is completed or earlier if the engagement is terminated by either party. Aurora is paid the hourly rates set forth on Schedule A to the CRO Agreement and is reimbursed for its expenses actually incurred in providing the services. The CRO Agreement may be terminated by either party, in its sole discretion, for any reason and the termination is effective immediately upon the other party’s receipt of written notice of the termination.

Concentrations and Credit Risk

The Company’s accounts receivable are due from a variety of health care organizations and distributors throughout the world. No single customer accounted for more than 10% of revenue or accounts receivable for the comparable periods. The Company provides for uncollectible amounts when specific credit issues arise. Management’s estimates for uncollectible amounts have been adequate during prior periods, and management believes that all significant credit risks have been identified at September 30, 2017.

In the nine months ended September 30, 2017, Xtant purchased from Norwood Medical less than 10% of its operating products (See Note 13, “Related Party Transactions” below) and approximately 12% for the same period in 2016.

Use of Estimates

The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill, and intangible assets and liabilities; valuation allowances for trade receivables, inventory, and deferred income tax assets and liabilities; valuation of the warrant derivative liability, inventory, and estimates for the fair value of stock options grants and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.

Long-Lived Assets

Long-lived assets, including intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.

Goodwill

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized, instead they are tested for impairment at least annually and whenever events or circumstances indicate the carrying amount of such asset may not be recoverable. In its evaluation of goodwill, the Company performs an assessment of qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test. The Company conducts its annual impairment test on December 31 of each year.

Revenue Recognition

Revenue is recognized when all of the following criteria are met: a) the Company has entered into a legally binding agreement with the customer; b) the products or services have been delivered; c) the Company’s fee for providing the products and services is fixed or determinable; and d) collection of the Company’s fee is probable.

The Company’s policy is to record revenue net of any applicable sales, use, or excise taxes. If an arrangement includes a right of acceptance or a right to cancel, revenue is recognized when acceptance is received or the right to cancel has expired.

The Company ships to certain customers under consignment arrangements whereby the Company’s product is stored by the customer. The customer is required to report the use to the Company and upon such notice, the Company invoices the customer and revenue is recognized when the above criteria have been met.

Research and Development

Research and development costs, which are principally related to internal costs for the development of new devices and biologics and processes are expensed as incurred.

Other Income (Expense)

Other income (expense) primarily consists of non-recurring items that are outside of the normal Company’s operations such as other related legal expenses, gain or loss on the sale of fixed assets, restructuring costs.

Net Loss Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net income (loss) per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the three and nine months ended September 30, 2017 and 2016, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods. Dilutive earnings per share are not reported as their effects of including 7,231,286 and 1,794,792 outstanding stock options and warrants for the three and nine months ended September 30, 2017 and 2016, respectively, are anti-dilutive.

Fair Value of Financial Instruments

The carrying values of financial instruments, including trade accounts receivable, accounts payable, other accrued expenses and long-term debt, approximate their fair values based on terms and related interest rates.

The Company follows a framework for measuring fair value. The framework provides a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. During the nine months ended September 30, 2017 and 2016, there was no reclassification in financial assets or liabilities between Level 1, 2 or 3 categories.

The following table sets forth by level, within the fair value hierarchy, our liabilities that are measured at fair value on a recurring basis:

Warrant derivative liability

	As of September 30, 2017		As of December 31, 2016
Level 1		-		-
Level 2		-		-
Level 3	$	196,929	$	333,613

The valuation technique used to measure fair value of the warrant liability is based on a lattice valuation model and significant assumptions and inputs determined by us (See Note 9, “Warrants” below).

Level 3 Changes

The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2017:

Warrant derivative liability

Balance at January 1, 2017	$	333,613
Gain recognized in earnings in first six months of 2017		(156,233	)
Balance at June 30 , 2017	$	177,380
Loss recognized in earnings in third quarter of 2017		19,549
Balance at September 30, 2017	$	196,929

During the nine months ended September 30, 2017, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. The new standard was originally effective for reporting periods beginning after December 15, 2016 and early adoption was not permitted. On August 12, 2015, the FASB approved a one year delay of the effective date to reporting periods beginning after December 15, 2017, while permitting companies to voluntarily adopt the new standard as of the original effective date. The comprehensive new standard will supersede existing revenue recognition guidance and require revenue to be recognized when promised goods or services are transferred to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. Adoption of the new rules could affect the timing of revenue recognition for certain transactions. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The Company is currently evaluating the impacts of adoption and the implementation approach to be used.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available. While we are still evaluating the impact of our pending adoption of the new standard on our consolidated financial statements, we expect that upon adoption we will recognize ROU assets and lease liabilities and that the amounts could be material.

Equity

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Equity

(2) Equity

In connection with the offering of units pursuant to the subscription rights, referred to as the “Rights Offering,” the Company distributed to holders of its common stock and to holders of its convertible notes, at no charge, non-transferable subscription rights to purchase units. Each unit consisted of one share of common stock and one tradeable warrant representing the right to purchase one share of common stock (“Tradeable Warrants”). On October 31, 2016, the Company entered into a dealer-manager agreement (the “Dealer-Manager Agreement”) with Maxim Group LLC (“Maxim”), to engage Maxim as dealer-manager for the Rights Offering.

In the Rights Offering, holders received two subscription rights for each share of common stock, for each share of common stock underlying our convertible notes owned on the record date, October 21, 2016. Subscribers whose subscriptions otherwise would have resulted in their beneficial ownership of more than 4.99% of the Company’s common stock could elect to receive, in lieu of shares of common stock in excess of that threshold, pre-funded warrants to purchase the same number of shares of common stock for $0.01 (“Pre-Funded Warrants”), and the subscription price per unit consisting of a Pre-Funded Warrant in lieu of a share of common stock was reduced by the $0.01 exercise price. No Pre-Funded Warrants were sold in the Rights Offering.

The Rights Offering closed on November 14, 2016. The units were priced at $0.75 per unit with gross proceeds from the Rights Offering of approximately $3.8 million and the net proceeds from the Rights Offering of approximately $2.5 million after deducting fees and expenses payable, and after deducting other expenses payable by us and excluding any proceeds received upon exercise of any Tradeable Warrants issued in the offering. Each Tradeable Warrant is exercisable for a period of five years for one share of common stock at an exercise price of $0.90 per share. The Tradeable Warrants associated with the equity raised were subject to an analysis that resulted in the Tradeable Warrants being recorded as equity and a component of stockholder’s equity. After the one-year anniversary of issuance, we may redeem the Tradeable Warrants for $0.01 per Tradeable Warrant if the volume weighted average price of our common stock is above $2.25 for each of 10 consecutive trading days.

In connection with the Rights Offering, the Company paid to Maxim a cash fee equal to 7% of the gross proceeds received by us directly from exercises of Subscription Rights. We also reimbursed Maxim $75,000 for expenses incurred in connection with the Rights Offering.

Inventories, Net

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Inventories, Net

(3) Inventories, Net

Inventories consist of the following:

	September 30,		December 31,
	2017		2016
Current inventories:
Raw materials	$	4,236,912	$	4,833,403
Work in process		1,397,524		1,891,380
Finished goods		23,627,961		23,878,040
Gross current inventories		29,262,397		30,602,823
Reserve for obsolescence		(5,223,484)		(4,336,366)
Current inventories, net		24,038,913		26,266,457
Non-current inventories:
Finished goods		1,130,980		1,385,017
Reserve for obsolescence		(413,163)		(413,163)
Non-current inventories, net		717,817		971,854
Total inventories, net	$	24,756,730	$	27,238,311

The Company provides implants and biologic inventory on consignment through its various sales channels to logistically place the inventory near the anticipated surgical location. Consigned inventory was approximately $12.3 million and $11.2 million at September 30, 2017 and December 31, 2016, respectively.

Property and Equipment, Net

9 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

(4) Property and Equipment, Net

Property and equipment, net are as follows:

	September 30,		December 31,
	2017		2016
Equipment	$	4,501,118	$	4,629,754
Computer equipment		451,177		416,233
Computer software		523,526		529,726
Furniture and fixtures		214,770		181,566
Leasehold improvements		4,030,010		4,053,837
Vehicles		10,000		10,000
Surgical instruments		13,292,141		13,876,757
Total cost		23,022,742		23,697,873
Less: accumulated depreciation		(11,571,905)		(7,857,143)
Property and equipment, net	$	11,450,837	$	15,840,730

The Company deploys certain surgical instruments through its various sales channels for use with implant and biologic inventory to be utilized during surgical procedures. The instruments are classified as non-current assets within property and equipment and depreciated using the straight-line method over a five-year useful life. The net book value of consigned surgical instruments was approximately $6.7 million and $8.2 million at September 30, 2017 and December 31, 2016, respectively. Instruments are recorded at cost and are carried at Net book value (cost less accumulated depreciation).

Depreciation expense related to property and equipment, including property under capital lease, for the first nine months of 2017 and 2016 was $3,946,352 and $2,181,541, respectively.

The Company leases certain equipment under capital leases. For financial reporting purposes, minimum lease payments relating to the assets have been capitalized. As of September 30, 2017, the Company has recorded $1,552,366 gross assets in Equipment, and $493,331 of accumulated depreciation relating to assets under capital leases.

Intangible Assets

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

(5) Intangible Assets

Intangible assets consist of various patents with regard to processes for its products and intangible assets associated with the acquisition of X-spine.

The following table sets forth information regarding intangible assets:

	September 30,		December 31,
	2017		2016
Patents		840,733		747,249
Acquisition related intangibles:
Technology		28,698,700		28,698,700
Customer relationships		9,911,000		9,911,000
Tradename		4,543,300		4,543,300
Non-compete		40,500		40,500
Accumulated amortization		(11,486,131)		(7,999,939)
Intangible assets, net	$	32,548,102	$	35,940,810

Aggregate amortization expense:	$	3,486,192	$	4,479,010

The following is a summary of estimated future amortization expense for intangible assets as of September 30, 2017:

Remainder of 2017	$	1,166,392
2018		4,664,156
2019		4,554,596
2020		4,471,961
2021		4,214,615
Thereafter		13,476,382
Total	$	32,548,102

Accrued Liabilities

9 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Accrued Liabilities

(6) Accrued Liabilities

Accrued liabilities consist of the following:

	September 30,		December 31,
	2017		2016
Accrued stock compensation	$	270,338	$	213,758
Wages/commissions payable		2,467,437		3,330,578
Accrued integration expense		-		73,510
Accrued interest payable		8,194,347		3,090,585
Other accrued expenses		2,493,619		2,273,756
Accrued liabilities	$	13,425,741	$	8,982,187

Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Debt

(7) Debt

Convertible Note Indenture

On July 31, 2015, we completed an offering of $65 million aggregate principal amount of 6.00% convertible senior unsecured notes due 2021 (the “Notes”) in a private offering to qualified institutional buyers, as defined in Rule 144A under the Securities Act of 1933, as amended, when we entered into an Indenture with Wilmington Trust, National Association (the “Indenture”). ROS Acquisition Offshore LP (“ROS”) and OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) purchased $52 million aggregate principal amount of the Notes directly from the Company in the offering. On August 10, 2015, the initial purchaser exercised its option with respect to an additional $3 million aggregate principal amount of Notes.

At any time prior to the close of business on the second business day immediately preceding the maturity date, holders may convert their Notes into shares of Xtant common stock (together with cash in lieu of fractional shares) at an initial conversion rate of 257.5163 shares per $1,000 principal amount of Notes (which represents an initial conversion price of approximately $3.88 per share). However, a Note will not be convertible to the extent that such convertibility or conversion would result in the holder of that Note or any of its affiliates being deemed to beneficially own in excess of 9.99% of the then-outstanding shares of Xtant common stock. The conversion rate will be subject to an adjustment as described in the Indenture upon the occurrence of certain events.

We will not adjust the conversion rate for other events, such as for an issuance of our common stock for cash or in connection with an acquisition that may dilute our common stock thereby adversely affecting its market price. In addition, Xtant will, in certain circumstances, increase the conversion rate for holders who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indenture). No sinking fund is provided for the Notes. Xtant may not redeem the Notes at its option prior to their maturity. If a “fundamental change” (as defined in the Indenture) occurs, holders will have the right, at their option, to require us to repurchase their Notes at a cash price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date, subject to the right of holders of Notes on a record date to receive accrued and unpaid interest.

The Notes are Xtant’s senior, unsecured obligations, rank equal in right of payment with its existing and future unsecured indebtedness that is not junior to the Notes, are senior in right of payment to any of its existing and future indebtedness that is expressly subordinated to the Notes, and are effectively subordinated to its existing and future secured indebtedness to the extent of the value of the collateral securing such indebtedness. The Notes are structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent Xtant is not a holder thereof) preferred equity, if any, of its subsidiaries.

On April 14, 2016, we issued $2,238,166 aggregate principal amount of convertible senior unsecured notes “Additional Notes” in a private placement to ROS and Royalty Opportunities when we entered into a securities purchase agreement (the “Additional Notes Purchase Agreement”). The proceeds were utilized to pay interest due for both the Notes and the New Facility (described below) on April 15, 2016.

Both the Additional Notes and the Notes bear interest at a rate equal to 6.00% per year. Following the first interest payment date for the Notes, which was April 15, 2016 and July 15, 2016 for the Additional Notes, interest on the Notes will be payable semiannually in arrears on January 15 and July 15 of each year. Interest accrues on the Notes from the last date to which interest has been paid or duly provided for or, if no interest has been paid or duly provided for, from July 31, 2015 for the Notes, and April 14, 2016 for the Additional Notes. Unless earlier converted or repurchased, the Notes and Additional Notes will mature on July 15, 2021.

The Additional Notes may be converted into shares of our common stock (together with cash in lieu of fractional shares) at an initial conversion rate of 344.8276 shares per $1,000 principal amount of Notes (which represents an initial conversion price of approximately $2.90 per share).

On January 17, 2017, the Company entered into securities purchase agreements with Bruce Fund, Inc., Park West Partners International, Limited, Park West Investors Master Fund, Limited, and Telemetry Securities, L.L.C., to satisfy interest obligations that we owed to such parties under $16,000,000 of Notes issued to them under the Indenture. Pursuant to such agreement, the parties agreed to purchase from the Company a total of 843,289 shares of the Company’s common stock at a price of $0.5692 per share.

On January 17, 2017, the Company entered into a securities purchase agreement and certain related documents with ROS and Royalty Opportunities, to satisfy interest obligations that the Company owed to them pursuant to $52,000,000 of Notes issued to them under the Indenture. Pursuant to such agreement, ROS and Royalty Opportunities agreed to purchase from the Company a new series of 6% Convertible Senior Notes Due 2021 in the aggregate original principal amount of up to $1,560,000 (the “Indenture Notes”). The Indenture Notes are convertible into our common stock at a conversion price of $0.7589 per share, and mature on July 15, 2021.

On January 17, 2017, the Company also entered into a securities purchase agreement and certain related documents with ROS and Royalty Opportunities, to satisfy interest obligations that the Company owed to them pursuant to $2,238,166 of Additional Notes issued under the Additional Notes Purchase Agreement. Pursuant to such agreement, ROS and Royalty Opportunities agreed to purchase from the Company a new series of 6% convertible senior notes due 2021 in the aggregate original principal amount of up to $67,145 (collectively, the “PIK Notes”). The PIK Notes are convertible into our common stock at a conversion price of $0.7589 per share, and mature on July 15, 2021.

Effective March 31, 2017, the Company, ROS and Royalty Opportunities entered into a waiver letter (the “Indenture Waiver”) of the Indenture. Under the Indenture Waiver, ROS and Royalty Opportunities waived any non-compliance with the covenant set forth in Section 6.01(a)(vii) of the Indenture due to the going concern qualification included in the Company’s audit report for the year ended December 31, 2016.

ROS and Royalty Opportunities also entered into a waiver (the “Notes Waiver”) for defaults that occurred under multiple convertible promissory notes (including the Notes, the Additional Notes, the Indenture Notes and the PIK Notes). Under the Notes Waiver, ROS and Royalty Opportunities waived any non-compliance with the covenants set forth in Section 6.01(a)(vii) of their respective notes due to the going concern qualification included in the Company’s audit report for the year ended December 31, 2016.

Effective July 15, 2017, ROS, Royalty Opportunities, Bruce Fund Inc. (“Bruce Fund”), Park West Partners International, Limited (“PWPI ”), Park West Investors Master Fund, Limited (“PWIMF”) and Telemetry Securities, L.L.C (“Telemetry ” and, together with ROS, Royalty Opportunities, Bruce Fund, PWPI and PWIMF, collectively, the “Holders”) entered into an Omnibus Waiver which deferred interest accrued on the Holders’ convertible promissory notes. The Holders are registered holders of the Notes.

Under the Omnibus Waiver and pursuant to Section 9.02 of the Indenture and Section 10.13 of the Notes, the interest due July 15, 2017 on the Notes was deferred until August 15, 2017, to be paid in cash together with interest accrued on such interest from July 15, 2017 to the date of the payment thereof at a rate equal to 6.00% per annum plus 100 basis points. Also under the Omnibus Waiver, the Holders waived any event of default that has occurred under the Indenture or the Notes as a result of the Company’s failure to pay interest accrued on the Notes on July 15, 2017. The convertible interest due on July 15, 2017 under the Company’s various convertible promissory notes was deferred by the holders of such notes until August 15, 2017.

Effective August 15, 2017 and September 29, 2017, the Company, ROS and Royalty Opportunities entered into the Amendment and Waiver, and the Second Amendment and Waiver, respectively, which amended the certain Notes by moving the payment date of interest accrued on the Notes from July 15, 2017 to October 31, 2017. The amendments also waived any event of default that may have occurred as a result of the non-payment of interest on July 15, 2017. The interest payment due will include interest accrued on such interest from July 15, 2017 to the date of payment thereof at a rate equal to 6.00% per annum plus 100 basis points.

Effective August 16, 2017, the Company and Wilmington Trust, National Association, entered into the Amendment Number 1 to Indenture, which amended the existing Indenture. The amendment amended the Indenture by moving the payment date of interest accrued on notes issued under the Indenture from July 15, 2017 to September 30, 2017. The amendment also set the record date for the September 30 interest payment at June 30, 2017 and waived any event of default that may have occurred as a result of the non-payment of interest on July 15, 2017. The interest payment due on September 30, 2017 will include interest accrued on such interest from July 11, 2017 to the date of payment thereof at a rate equal to 6.00% per annum plus 100 basis points.

Amended and Restated Credit Agreement

On July 31, 2015 the Company recorded $42 million of principal debt pursuant to an Amended and Restated Credit Agreement (the “New Facility”) with ROS Acquisition Offshore LP (“ROS”) and OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) with a maturity date (the “Maturity Date”) of July 31, 2020. Interest under the New Facility is bifurcated into a “cash pay” portion and a “payment-in-kind” (“PIK”) portion. Until June 30, 2018 (the “First Period”), interest on loans outstanding under the New Facility will accrue at a rate equal to the sum of (a) 9% per annum, which portion of interest will be payable in cash, plus (b) additional interest (“PIK Interest”) in an amount equal to (i) the sum of 14% per annum, plus the higher of (x) the LIBO Rate and (y) 1% per annum, minus (ii) 9% per annum, which portion of interest will be payable “in kind”. On or after June 30, 2018 until the New Facility is repaid in full (the “Second Period”), interest on loans outstanding under the New Facility will accrue at a rate equal to the sum of (a) 12% per annum, which portion of interest will be payable in cash, plus (b) PIK Interest in an amount equal to the difference of (i) the sum of 14% per annum, plus the higher of (x) the LIBO Rate and (y) 1% per annum, minus (ii) 12% per annum, which portion of interest will be payable “in kind.” In both the First Period and the Second Period, the portion of accrued interest constituting PIK Interest will not be payable in cash but will instead be added to the principal amount outstanding under the New Facility. However, at our option, we may choose to make any “payment-in-kind” interest payment in cash. Until the third anniversary of the closing date of the New Facility, we will not be allowed to voluntarily prepay the New Facility. Whenever loans outstanding under the New Facility are prepaid or paid, whether voluntarily, involuntarily or on the Maturity Date, a fee of 7.5% on the amount paid will be due and payable. The New Facility contains financial and other covenant requirements, including, but not limited to, financial covenants that require the Company to maintain revenue and liquidity at levels set forth in the New Facility and ensure that the Company’s senior consolidated leverage ratio does not exceed levels set forth in the New Facility. The New Facility also restricts us from making any payment or distribution with respect to, or purchasing, redeeming, defeasing, retiring or acquiring, the Notes other than payments of scheduled interest on the Notes, issuance of shares of our common stock upon conversion of the Notes, and payment of cash in lieu of fractional shares. The loans under the New Facility are guaranteed by Xtant and its current and future subsidiaries and are secured by substantially all of the current and future assets of Xtant and its subsidiaries.

Approximately $4.9 million of expenses were incurred in conjunction with the acquisition, the issuance of convertible debt and the amendment and restatement of our credit facility with ROS and Royalty Opportunities. Of that amount, approximately $4.7 million of debt issuance costs was capitalized and is being amortized over the life of the debt.

We have entered into several amendments to the New Facility, and the material provisions of such amendments that have been subsequently modified or restated are summarized below.

On July 29, 2016 we entered into the fourth amendment to the New Facility which provided for an additional “Tranche A Commitment” in an amount up to $1,000,000 from the OrbiMed Purchasers, which was made available to us on July 29, 2016 for a total of $43 million loan payable to ROS and Royalty Opportunities.

On September 27, 2016, we entered into the sixth amendment to the New Facility which increased the fee on any amounts paid under the New Facility from 7.5% to 9.0%. Under the sixth amendment, regular interest will not accrue during the period from July 1, 2016 to September 30, 2016; however, during such period, PIK Interest will accrue at a rate per annum equal to 9.00%, and such PIK Interest will be added to the outstanding principal amount of the loans at September 30, 2016. The sixth amendment also modifies the negative covenants of the New Facility by increasing the amount of purchase money indebtedness and capitalized lease liabilities allowed to be incurred by us and lowering the minimum revenue base for the quarters ending September 30, 2016 and December 31, 2016.

The seventh amendment (effective December 31, 2016), eighth amendment (effective January 13, 2017), ninth amendment (effective January 31, 2017), tenth amendment (effective February 14, 2017), eleventh amendment (effective February 28, 2017), twelfth amendment (effective March 31, 2017), thirteenth amendment (effective April 30, 2017), fourteenth amendment (effective May 11, 2017), fifteenth amendment (effective June 30, 2017), sixteenth amendment (effective July 15, 2017), seventeenth amendment (effective August 11, 2017) and eighteenth amendment (effective September 29, 2017) deferred our accrued interest payment date for the fiscal quarter ended December 31, 2016, until October 31, 2017. The interest due on July 15, 2017 was $1,147,329.47, plus interest accrued on such interest from January 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate (as defined in the New Facility) for the fiscal quarter ended on December 31, 2016, or 1%.

The seventh amendment also made several other modifications, all of which were restated by the twelfth amendment described below. In addition to the December 31, 2016 deferral, the twelfth amendment, thirteenth amendment, fourteenth amendment, fifteenth amendment, sixteenth amendment, seventeenth amendment and eighteenth amendment deferred our accrued interest payment date for the fiscal quarter ended on March 31, 2017 until October 31, 2017. The interest due on July 15, 2017 for the fiscal quarter ended on March 31, 2017 was $1,139,597, plus interest accrued on such interest from April 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on March 31, 2017, or 1%. The fifteenth amendment, sixteenth amendment, seventeenth amendment and eighteenth amendment deferred our accrued interest payment date for the fiscal quarter ended on June 30, 2017 until October 31, 2017. The interest due on July 15, 2017 for the fiscal quarter ended on June 30, 2017 was $1,169,544, plus interest accrued on such interest from July 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%. Finally, the eighteenth amendment deferred our accrued interest payment date for the fiscal quarter ended on September 30, 2017 until October 31, 2017. The interest due on October 31, 2017 for the fiscal quarter ended on September 30, 2017 will be $1,482,406, plus interest accrued on such interest from October 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%.

The twelfth amendment waived any non-compliance with the covenant set forth in Section 7.1(c) of the New Facility due to the going concern qualification included in the Company’s audit report for the year ended December 31, 2016.

Effective May 11, 2017, the parties entered into the fourteenth amendment to the New Facility and the amended guarantors were Xtant, X-Spine and Xtant Medical Inc., collectively. X-Spine was defined as the Additional Delayed Draw Borrower of new term loans. The fourteenth amendment allowed for X-Spine to make additional term loans with ROS and Royalty Opportunities in an aggregate amount of up to $15,000,000. The amount of each loan draw made by X-Spine is subject to the Company’s production of a thirteen-week cash flow forecast that is approved by ROS and Royalty Opportunities. The funding of each Additional Delayed Draw Loan by ROS and Royalty Opportunities is subject to the satisfaction (or waiver in writing by each lender) of conditions precedent, including closing certificate, delivery of budget, the hiring of a CRO, a payoff letter from the Bank (see below), and other satisfactory documents.

The seventeenth amendment modified the minimum revenue base covenant for the quarters ending June 30, 2017, and September 30, 2017. The eighteenth amendment modified the minimum liquidity financial covenant of the New Facility by allowing the Company and its subsidiaries to maintain a liquidity amount of not less than $500,000 until October 31, 2017. At all times after October 31, 2017, the liquidity of the Company and its subsidiaries must not be less than $5,000,000. The New Facility Amendment also modified the consolidated senior leverage ratio financial covenant of the New Facility by moving the commencement date of the covenant from the most recent four fiscal quarters ended September 30, 2017, to the most recent four fiscal quarters ended December 31, 2017.

Revolving Credit Line Loan and Security Agreement

On May 25, 2016, we entered into a Loan and Security Agreement (the “LSA”) with Silicon Valley Bank, a California corporation (the “Bank”), pursuant to which the Bank agreed to provide us with a revolving line of credit in the aggregate principal amount of $6,000,000.

On August 12, 2016, we entered into a First Loan Modification Agreement (the “Modification Agreement”) with the Bank, which amended certain provisions of the LSA. Pursuant to the terms of the Modification Agreement, the Bank increased the aggregate principal amount of the revolving line of credit to $11,000,000.

On May 12, 2017, the Company paid off all obligations under the LSA with funds from the above New Facility.

Long-term debt consists of the following:

	September 30,		December 31,
	2017		2016
Loan payable to ROS and Royalty Opportunities (See details above)	$	55,787,095	$	43,000,000
PIK Interest payable to ROS and Royalty Opportunities		10,109,062		7,648,776
6% convertible senior unsecured notes due 2021 (See details above)		71,865,311		70,238,166
Gross long-term debt		137,761,468		120,886,942
Less: debt classified as a current liability, less issuance costs		(65,609,693)		-
Less: total debt issuance costs		(1,370,563)		(1,665,508)
Long-term debt, less issuance costs	$	70,781,212	$	119,221,434

The loan payable and PIK interest payable to ROS and Royalty Opportunities ("lenders") includes a minimum revenue covenant requiring the Company to achieve minimum revenue benchmarks on a calendar quarter basis. A waiver was obtained from the lenders for not achieving the minimum revenue covenant for the third quarter ended September 30, 2017. The minimum revenue covenant is $27.5 million for the fourth quarter ended December 31, 2017. The Company does not anticipate achieving this minimum revenue covenant and it is not assured the lenders will provide a waiver of this anticipated covenant violation at this future date. The Company has classified this debt as a current liability in its September 30, 2017 balance sheet.

The following is a summary of maturities due on the debt as of September 30, 2017:

Remainder of 2017	$	-
2018		-
2019		-
2020		65,896,157
2021		71,865,311
Thereafter		-
Total	$	137,761,468

Stock-Based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

(8) Stock-Based Compensation

The Amended and Restated Xtant Medical Equity Incentive Plan (the “Plan”) provides for stock awards, including options and performance stock awards, to be granted to employees, consultants, independent contractors, officers and directors. The purpose of the Plan is to enable us to attract, retain and motivate key employees, directors and, on occasion, independent consultants, by providing them with stock options and restricted stock grants. Stock options granted under the Plan may be either incentive stock options to employees, as defined in Section 422A of the Internal Revenue Code of 1986, or non-qualified stock options. The Plan is administered by the compensation committee of our board of directors. Stock options granted under the Plan are generally not transferable, vest in installments over the requisite service period and are exercisable during the stated contractual term of the option only by such optionee. Executives may be awarded an option to purchase common stock outside of the Plan (collectively the “Non-Plan Grants”), as described below. The exercise price of all incentive stock options granted under the Plan must be at least equal to the fair market value of the shares of common stock on the date of the grant. 1,900,000 shares are currently authorized under the Plan and at September 30, 2017, we had approximately 960,000 shares available for issuance which are authorized, but unissued or reacquired shares.

Stock compensation expense recognized in the condensed consolidated statements of operations for the nine months ended September 30, 2017 and 2016 is based on awards ultimately expected to vest and reflects an estimate of awards that will be forfeited. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. No stock options were issued in the first nine months of 2017 or 2016.

Stock option activity, including options granted under the Plan and the Non-Plan Grants, was as follows:

	2017						2016
					Weighted						Weighted
					Average						Average
			Weighted		Fair				Weighted		Fair
			Average		Value at				Average		Value at
			Exercise		Grant				Exercise		Grant
	Shares		Price		Date		Shares		Price		Date
Outstanding at January 1		1,205,913	$	5.21	$	2.82		664,081	$	10.64	$	5.32
Cancelled or expired		(265,958)		3.40		1.90		(105,275)		9.48		4.50
Outstanding at September 30		939,955	$	5.73	$	3.08		558,806	$	10.85	$	5.42
Exercisable at September 30		382,996	$	11.44	$	5.68		409,179	$	12.67	$	6.15

The aggregate intrinsic value of options outstanding as of September 30, 2017 was zero because the closing price of the stock at September 30, 2017 was less than the strike price of all options outstanding. As of September 30, 2017, there were 556,959 unvested options with a weighted average fair value at the grant date of $1.80 per option. As of September 30, 2017, we had approximately $376,778 in compensation expense related to unvested awards not yet recognized.

Total share based compensation recognized for employees, directors and consultants was $412,888 and $479,888 for the nine months ended September 30, 2017 and 2016, respectively.

On July 5, 2016, the Company granted 130,804 restricted stock units and options to our six independent Directors of the Company (Messrs. Lopach, Swanson, Deedrick, Buckman, Mazzocchi and Timko). This group of annual awards valued at approximately $40,000 per director vested on July 5, 2017 and were granted when the stock price was $1.99 per share. The total expense is being recognized ratably over the period as Non-cash consulting expense. In the nine months ended September 30, 2017, $50,444 was expensed.

On July 25, 2017, the Company granted 311,688 restricted stock units to the independent Directors of the Company. These restricted shares will be vested on July 25, 2018 and were granted when the stock price was $0.77 per share. The total expense of $240,000 will be recognized ratably over the period as Non-cash consulting expense. In the nine months ended September 30, 2017 $60,000 was expensed.

Effective January 21, 2017, Daniel Goldberger resigned as Chief Executive Officer and a director of the Company and Carl O’Connell was appointed as Interim Chief Executive Officer of the Company. Mr. Goldberger’s Non-plan Grant option to purchase 200,000 shares of our common stock at $6.00 was cancelled. In connection with his departure, the Company entered into a Separation Agreement and General Release (the “Separation Agreement”) on January 21, 2017, with Mr. Goldberger. The Separation Agreement provides that, among other things, Mr. Goldberger will provide transitional consulting services to the Company for a period of up to three (3) months from the date of the Separation Agreement at the request of the Company’s board. Mr. Goldberger did receive an additional $130,000 in compensation payable in equal monthly installments of $43,333 beginning April 21, 2017 and ending June 21, 2017. Further, the Company determined that Mr. Goldberger earned a partial bonus for 2016 and such bonus was paid in accordance with the applicable Company policies.

Effective February 17, 2017, our board of directors appointed Carl O’Connell to serve as the Chief Executive Officer and a director of the Company after serving as Interim Chief Executive Officer of the Company since January 21, 2017. Mr. O’Connell serves as a Class I Director until the 2018 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. As Mr. O’Connell is an officer of the Company, he does not qualify as an independent director and does not serve on any committees of the Board. On October 6, 2016, we issued an option to purchase 300,000 shares of our common stock as Non-Plan Grants at $1.11 per share to Carl O’Connell which remain outstanding and the related expense recognized in the nine months ended September 30, 2017 was $22,921.

Warrants

9 Months Ended

Sep. 30, 2017

Warrants and Rights Note Disclosure [Abstract]

Warrants

(9) Warrants

The following table summarizes our warrant activities for the nine months ended September 30, 2017:

			Weighted
	Common		Average
	Stock		Exercise
	Warrants		Price
Outstanding as of January 1, 2016		1,278,566	$	8.45
Issued		5,055,345		0.90
Expired		(42,580)		31.73
Outstanding at January 1, 2017		6,291,331	$	2.23
Issued		-		-
Expired		-		-
Outstanding at September 30, 2017		6,291,331	$	2.23

We utilize a lattice valuation model to determine the fair market value of the warrants accounted for as liabilities. The lattice valuation model accommodates the probability of exercise price adjustment features as outlined in the warrant agreements. We recorded an unrealized gain of $136,684 resulting from the change in the fair value of the warrant derivative liability for the first nine months of 2017. Under the terms of some of our warrant agreements, at any time while the warrant is outstanding, the exercise price per share can be reduced to the price per share of future subsequent equity sales of our common stock or a common stock equivalent that is lower than the exercise price per share as stated in the warrant agreement.

The estimated fair value was derived using a valuation model with the following weighted-average assumptions:

	Quarter Ended
	September 30,
	2017			2016
Value of underlying common stock (per share)	$	0.72		$	1.13
Risk free interest rate		1.87	%		2.21	%
Expected term		4.9	years		3.25	years
Volatility		98	%		79	%
Dividend yield		0	%		0	%

The following table summarizes our activities related to warrants accounted for as a derivative liability for the nine months ended September 30, 2017 and 2016:

	2017		2016
Balance at January 1,		1,125,119		1,125,119
Derivative warrants issued, exercised and expired		-		-
Balance at September 30,		1,125,119		1,125,119

Commitments and Contingencies

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

(10) Commitments and Contingencies

Operating Leases

We lease five office facilities under non-cancelable operating lease agreements with expiration dates between 2019 and 2025. We have the option to extend the five leases for up to another ten-year term and for one facility, we have the right of first refusal on any sale.

Future minimum payments for the next five years and thereafter as of September 30, 2017, under these leases, are as follows:

Remainder of 2017	$	199,491
2018		806,747
2019		668,807
2020		396,263
2021		375,289
Thereafter		1,038,416
Total	$	3,485,013

Rent expense was $593,660 and $661,219 for the nine months ended September 30, 2017 and 2016, respectively. Rent expense is determined using the straight-line method of the minimum expected rent paid over the term of the agreement. We have no contingent rent agreements.

Capital Leases

Future minimum payments for the next five years and thereafter as of September 30, 2017, under capital leases for equipment, are as follows:

Remainder of 2017	$	123,634
2018		494,535
2019		462,544
2020		181,714
2021		-
Thereafter		-
Total minimum lease payments		1,262,427
Less amount representing interest		(285,321)
Present value of obligations under capital leases		977,106
Less current portion		(319,095)
Long-term capital lease obligations	$	658,011

Litigation

On August 10, 2017, a civil suit complaint was filed against Xtant in the United States District Court, District of Nevada by Axis Spine NV, LLC (“Axis”), Case No. 2:17-CV-02147-APG-VCF. The complaint alleges breach of contract, breach of the implied covenant of good faith and fair dealing, and tortious interference with prospective economic advantage with respect to an alleged medical device distribution relationship between the parties. Specifically, Axis alleges that Xtant owes payments to Axis for its medical device distributions. Axis seeks relief in the form of damages in an amount in excess of $972,283. Xtant filed a motion to dismiss on September 15, 2017, and is awaiting the court’s ruling. The Company recorded reserves for outstanding net receivables due from Axis and consigned assets in Axis’ possession totaling $1,342,049 in the third quarter ended September 30, 2017.

Indemnifications

Our arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party’s intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying condensed consolidated financial statements.

We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request.

Income Taxes

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Income Taxes

(11) Income Taxes

In evaluating the realizability of the net deferred tax assets, we take into account a number of factors, primarily relating to the ability to generate taxable income. Where it is determined that it is likely that we will be unable to realize deferred tax assets, a valuation allowance is established against the portion of the deferred tax asset. Because it cannot be accurately determined when or if we will become profitable, a valuation allowance was provided against the entire deferred income tax asset balance.

The Company did not recognize any interest or penalties related to income taxes for the nine months ended September 30, 2017 and 2016.

Supplemental Disclosure of Cash Flow Information

9 Months Ended

Sep. 30, 2017

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow Information

(12) Supplemental Disclosure of Cash Flow Information

Supplemental cash flow information is as follows:

	Nine Months Ended
	September 30,
	2017		2016
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest	$	448,999	$	4,530,170
Non-cash activity:
Issuance of capital leases	$	103,483	$	967,221
Issuance of shares associated with legal settlement	$	-	$	225,000
Interest converted into common stock	$	480,000	$	-

Related Party Transactions

9 Months Ended

Sep. 30, 2017

Related Party Transactions

(13) Related Party Transactions

Darrel Holmes, our former Chief Operating Officer of our Bacterin subsidiary, serves on the board of American Donor Services Inc. (“ADS”). Mr. Holmes receives $5,000 per year for his service to ADS. ADS recovers tissue from donors and we reimburse ADS for its recovery fees, which are comprised primarily of labor costs. The approximate aggregate amount of all transactions with ADS for the nine months ended September 30, 2017 and 2016 was $906,216 and $844,643, respectively. Our relationship with ADS has benefited us, as ADS provides us with current donors and a pipeline for future donors, which is necessary to our success.

Certain of X-spine’s former shareholders own over 10% of our common stock in conjunction with the acquisition, and have owned a controlling interest of X-spine’s largest supplier, Norwood Tool Company d/b/a Norwood Medical. In the first nine months of 2017, Xtant purchased from Norwood Medical less than 10% of its operating products and approximately 12% for the same period in 2016.

Unless delegated to the Compensation Committee by the board of directors, the Audit Committee or the disinterested members of the full board of directors reviews and approves all related party transactions.

Segment and Geographic Information

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment and Geographic Information

(14) Segment and Geographic Information

The Company’s management reviews financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture and marketing of orthopedic medical products and devices.

The Company attributes revenues to geographic areas based on the location of the customer. Approximately 97% and 95% of sales were in the United States, respectively, for the nine months ended September 30, 2017 and 2016. Total revenue by major geographic area is as follows:

	Nine Months Ended
	September 30,
	2017		2016
United States	$	61,442,431	$	62,253,220
Rest of world		1,837,481		3,278,659
Total revenue	$	63,279,912	$	65,531,879

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

(15) Subsequent Events

Amendment Number 2 to Indenture

Effective October 2, 2017, the Company and Wilmington Trust, National Association, entered into the Amendment Number 2 to Indenture, which amended the Indenture by moving the payment date of interest accrued on notes issued under the Indenture from September 30, 2017 to October 31, 2017. The amendment also set the record date for the October 31 interest payment at June 30, 2017 and waived any event of default that may have occurred as a result of the non-payment of interest on July 15, 2017. The interest payment due on October 31, 2017 includes interest accrued on such interest from July 15, 2017 to the date of payment thereof at a rate equal to 6.00% per annum plus 100 basis points.

Consolidation of Fixation Operations to Montana and Closure of Dayton Facility

On October 6, 2017, the Company announced the closure of its Dayton, Ohio facility and the transitioning of its fixation operations to the Company’s headquarters in Belgrade, Montana. The Dayton, Ohio facility employs approximately 55 employees in various quality assurance, regulatory, inventory management, finance, engineering, and distribution positions. Many of these functions will ultimately transition to our Montana facility. Once the transition is completed, annualized cost savings are anticipated to be in excess of $2 million, resulting from right-sizing the organization and reduction in facilities. The one-time cost for executing this change is estimated to be $1.5 million will be recorded through March 31, 2018. The Company will file the Worker Adjustment and Retraining Notification with the State of Ohio and the Department of Job and Family Services.

Nineteenth Amendment to Amended and Restated Credit Agreement

Effective October 31, 2017, Bacterin, the Company, X-Spine, and Xtant Medical, Inc., collectively as the guarantors, and ROS and Royalty Opportunities, entered into the Nineteenth Amendment to Amended and Restated Credit Agreement, which amended the New Facility. The amendment further deferred Bacterin’s accrued interest payment date for the fiscal quarters ended on December 31, 2016, March 31, 2017, June 30, 2017 and September 30, 2017 until November 30, 2017.

The interest due on November 30, 2017 for the fiscal quarter ended on December 31, 2016 will be $1,147,329, plus interest accrued on such interest from January 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on December 31, 2016, or 1%. The interest due on November 30, 2017 for the fiscal quarter ended on March 31, 2017 will be $1,139,597, plus interest accrued on such interest from April 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on March 31, 2017, or 1%. The interest due on November 30, 2017 for the fiscal quarter ended on June 30, 2017 will be $1,303,936, plus interest accrued on such interest from July 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%. The interest due on November 30, 2017 for the fiscal quarter ended on September 30, 2017 will be $1,482,406, plus interest accrued on such interest from October 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%.

The amendment also modified the minimum liquidity financial covenant of the New Facility by allowing the Company and its subsidiaries to maintain a liquidity amount of not less than $500,000 until November 30, 2017. At all times after November 30, 2017, the liquidity of the Company and its subsidiaries must not be less than $5,000,000.

Amendment Number 3 to Indenture

Effective October 31, 2017, the Company and Wilmington Trust, National Association, entered into the Amendment Number 3 to Indenture, which amended the Indenture by moving the payment date of interest accrued on notes issued under the Indenture from October 31, 2017 to November 30, 2017. The amendment also set the record date for the November 30 interest payment at June 30, 2017 and waived any event of default that may have occurred as a result of the non-payment of interest on July 15, 2017. The interest payment due on November 30, 2017 will include interest accrued on such interest from July 15, 2017 to the date of payment thereof at a rate equal to 6.00% per annum plus 100 basis points.

Third Amendment and Waiver to Convertible Promissory Notes

Effective October 31, 2017, the Company, ROS and Royalty Opportunities entered into the Third Amendment and Waiver, which amended certain Notes held by ROS and Royalty Opportunities. The amendment amended the Notes by moving the payment date of interest accrued on the Notes from October 31, 2017 to November 30, 2017. The amendment also waived any event of default that may have occurred as a result of the non-payment of interest on July 15, 2017. The interest payment due on November 30, 2017 will include interest accrued on such interest from July 15, 2017 to the date of payment thereof at a rate equal to 6.00% per annum plus 100 basis points.

Waiver to Amended and Restated Credit Agreement

Effective November 14, 2017, Bacterin, the Company, X-Spine, Xtant Medical, ROS and Royalty Opportunities, entered into a Waiver to Amended and Restated Credit Agreement, which waived any non-compliance with the minimum revenue base covenant for the quarter ending September 30, 2017.

Restatement of Financial Statements

On November 20, 2017, the Company filed a Current Report on Form 8-K that stated the Company’s unaudited financial statements for the quarters ended March 31, 2017 and June 30, 2017 should no longer be relied upon because of an error in the quarter ended March 31, 2017, pertaining to accumulated depreciation on surgical instruments as of that date. Correcting the error requires a decrease in property and equipment, net, in the amount of $618,000 and a related increase in cost of goods sold. All such corrections have been properly accounted for in this Form 10-Q and the Company plans to restate the applicable quarterly reports as soon as reasonable practicable.

Our principal executive and principal financial officers reevaluated the effectiveness of our disclosure controls and procedures as of March 31, 2017 and June 30, 2017, as to whether the errors identified were the result of a material weakness in our internal control over financial reporting. The Company reconsidered whether our existing disclosure controls and procedures around the presentation and disclosure of property and equipment and accumulated depreciation are effective. Based on this assessment, our Chief Executive Officer and Deputy Restructuring Officer concluded that controls over property and equipment and accumulated depreciation were not effective as of March 31, 2017 and June 30, 2017, and that therefore our disclosure controls and procedures were not effective.

To remediate the material weakness surrounding the presentation and disclosure of the recognition of property and equipment and related accumulated depreciation, the Company has reviewed internal controls, changed supervisory personnel and improved the accounting review processes in this financial reporting area. Additional review and oversight is being exercised in the recording of property and equipment activity.

Business Description and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description

Business Description

Going Concern

Going Concern

CRO Agreement

CRO Agreement

Concentrations and Credit Risk

Concentrations and Credit Risk

Use of Estimates

Use of Estimates

Long-Lived Assets

Long-Lived Assets

Goodwill

Goodwill

Revenue Recognition

Revenue Recognition

Research and Development

Research and Development

Research and development costs, which are principally related to internal costs for the development of new devices and biologics and processes are expensed as incurred.

Other Income (Expense)

Other Income (Expense)

Net Loss Per Share

Net Loss Per Share

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table sets forth by level, within the fair value hierarchy, our liabilities that are measured at fair value on a recurring basis:

Warrant derivative liability

	As of		As of
	September 30,		December 31,
	2017		2016
Level 1		-		-
Level 2		-		-
Level 3	$	196,929	$	333,613

Level 3 Changes

Warrant derivative liability

Balance at January 1, 2017	$	333,613
Gain recognized in earnings in first six months of 2017		(156,233)
Balance at June 30 , 2017	$	177,380
Loss recognized in earnings in third quarter of 2017		19,549
Balance at September 30, 2017	$	196,929

During the nine months ended September 30, 2017, the Company did not change any of the valuation techniques used to measure its liabilities at fair value.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Business Description and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Assets and Liabilities Measured on Recurring Basis

Warrant derivative liability

	As of		As of
	September 30,		December 31,
	2017		2016
Level 1		-		-
Level 2		-		-
Level 3	$	196,929	$	333,613

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

Warrant derivative liability

Balance at January 1, 2017	$	333,613
Gain recognized in earnings in first six months of 2017		(156,233)
Balance at June 30 , 2017	$	177,380
Loss recognized in earnings in third quarter of 2017		19,549
Balance at September 30, 2017	$	196,929

Inventories, Net (Tables)

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:

	September 30,		December 31,
	2017		2016
Current inventories:
Raw materials	$	4,236,912	$	4,833,403
Work in process		1,397,524		1,891,380
Finished goods		23,627,961		23,878,040
Gross current inventories		29,262,397		30,602,823
Reserve for obsolescence		(5,223,484)		(4,336,366)
Current inventories, net		24,038,913		26,266,457
Non-current inventories:
Finished goods		1,130,980		1,385,017
Reserve for obsolescence		(413,163)		(413,163)
Non-current inventories, net		717,817		971,854
Total inventories, net	$	24,756,730	$	27,238,311

Property and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net are as follows:

	September 30,		December 31,
	2017		2016
Equipment	$	4,501,118	$	4,629,754
Computer equipment		451,177		416,233
Computer software		523,526		529,726
Furniture and fixtures		214,770		181,566
Leasehold improvements		4,030,010		4,053,837
Vehicles		10,000		10,000
Surgical instruments		13,292,141		13,876,757
Total cost		23,022,742		23,697,873
Less: accumulated depreciation		(11,571,905)		(7,857,143)
Property and equipment, net	$	11,450,837	$	15,840,730

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The following table sets forth information regarding intangible assets:

	September 30,		December 31,
	2017		2016
Patents		840,733		747,249
Acquisition related intangibles:
Technology		28,698,700		28,698,700
Customer relationships		9,911,000		9,911,000
Tradename		4,543,300		4,543,300
Non-compete		40,500		40,500
Accumulated amortization		(11,486,131)		(7,999,939)
Intangible assets, net	$	32,548,102	$	35,940,810

Aggregate amortization expense:	$	3,486,192	$	4,479,010

Schedule of Estimated Amortization Expense for Intangible Assets

The following is a summary of estimated future amortization expense for intangible assets as of September 30, 2017:

Remainder of 2017	$	1,166,392
2018		4,664,156
2019		4,554,596
2020		4,471,961
2021		4,214,615
Thereafter		13,476,382
Total	$	32,548,102

Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following:

	September 30,		December 31,
	2017		2016
Loan payable to ROS and Royalty Opportunities (See details above)	$	55,787,095	$	43,000,000
PIK Interest payable to ROS and Royalty Opportunities		10,109,062		7,648,776
6% convertible senior unsecured notes due 2021 (See details above)		71,865,311		70,238,166
Gross long-term debt		137,761,468		120,886,942
Less: debt classified as a current liability, less issuance costs		(65,609,693)		-
Less: total debt issuance costs		(1,370,563)		(1,665,508)
Long-term debt, less issuance costs	$	70,781,212	$	119,221,434

Schedule of Maturities of Long-term Debt

The following is a summary of maturities due on the debt as of September 30, 2017:

Remainder of 2017	$	-
2018		-
2019		-
2020		65,896,157
2021		71,865,311
Thereafter		-
Total	$	137,761,468

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

Stock option activity, including options granted under the Plan and the Non-Plan Grants, was as follows:

	2017						2016
					Weighted						Weighted
					Average						Average
			Weighted		Fair				Weighted		Fair
			Average		Value at				Average		Value at
			Exercise		Grant				Exercise		Grant
	Shares		Price		Date		Shares		Price		Date
Outstanding at January 1		1,205,913	$	5.21	$	2.82		664,081	$	10.64	$	5.32
Cancelled or expired		(265,958)		3.40		1.90		(105,275)		9.48		4.50
Outstanding at September 30		939,955	$	5.73	$	3.08		558,806	$	10.85	$	5.42
Exercisable at September 30		382,996	$	11.44	$	5.68		409,179	$	12.67	$	6.15

Warrants (Tables)

9 Months Ended

Sep. 30, 2017

Warrants and Rights Note Disclosure [Abstract]

Schedule of Warrant Activity

The following table summarizes our warrant activities for the nine months ended September 30, 2017:

			Weighted
	Common		Average
	Stock		Exercise
	Warrants		Price
Outstanding as of January 1, 2016		1,278,566	$	8.45
Issued		5,055,345		0.90
Expired		(42,580)		31.73
Outstanding at January 1, 2017		6,291,331	$	2.23
Issued		-		-
Expired		-		-
Outstanding at September 30, 2017		6,291,331	$	2.23

Schedule of Warrant Valuation Assumptions

The estimated fair value was derived using a valuation model with the following weighted-average assumptions:

	Quarter Ended
	September 30,
	2017			2016
Value of underlying common stock (per share)	$	0.72		$	1.13
Risk free interest rate		1.87	%		2.21	%
Expected term		4.9	years		3.25	years
Volatility		98	%		79	%
Dividend yield		0	%		0	%

Schedule of Warrants Activities Used In Derivative Liability

The following table summarizes our activities related to warrants accounted for as a derivative liability for the nine months ended September 30, 2017 and 2016:

	2017		2016
Balance at January 1,		1,125,119		1,125,119
Derivative warrants issued, exercised and expired		-		-
Balance at September 30,		1,125,119		1,125,119

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

Future minimum payments for the next five years and thereafter as of September 30, 2017, under these leases, are as follows:

Remainder of 2017	$	199,491
2018		806,747
2019		668,807
2020		396,263
2021		375,289
Thereafter		1,038,416
Total	$	3,485,013

Schedule of Future Minimum Lease Payments for Capital Leases

Future minimum payments for the next five years and thereafter as of September 30, 2017, under capital leases for equipment, are as follows:

Remainder of 2017	$	123,634
2018		494,535
2019		462,544
2020		181,714
2021		-
Thereafter		-
Total minimum lease payments		1,262,427
Less amount representing interest		(285,321)
Present value of obligations under capital leases		977,106
Less current portion		(319,095)
Long-term capital lease obligations	$	658,011

Segment and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Schedule of Revenues by Geographic Region

Total revenue by major geographic area is as follows:

	Nine Months Ended
	September 30,
	2017		2016
United States	$	61,442,431	$	62,253,220
Rest of world		1,837,481		3,278,659
Total revenue	$	63,279,912	$	65,531,879

Business Description and Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	$ 196,929	$ 333,613
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant derivative liability	$ 196,929	$ 333,613

Business Description and Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 177,380	$ 333,613
Gain (loss) recognized in earnings	19,549	(156,233)
Balance	$ 196,929	$ 177,380

Business Description and Summary of Significant Accounting Policies (Details Textual) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,231,286	1,794,792	7,231,286	1,794,792
Sales Revenue, Net [Member] \| One Vendor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Concentration Risk, Percentage			10.00%	12.00%

Equity (Details Textual) - USD ($)		9 Months Ended
Equity (Details Textual) - USD ($)	Nov. 14, 2016	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.90	$ 2.23	$ 2.23	$ 8.45
Equity Method Investment, Ownership Percentage		4.99%
Rights Offering Price Per Unit	$ 0.75
Gross Proceeds From Issuance Of Rights Shares	$ 3,800,000
Net Proceeds From Issuance Of Rights Shares	$ 2,500,000
Maxim Group LLC [Member]
Schedule of Equity Method Investments [Line Items]
Rights Offering Cash Fee Percentage Paid To Gross Proceeds		7.00%
Rights Offering Cash Fee Reimbursed		$ 75,000
Tradable Warrants [Member]
Schedule of Equity Method Investments [Line Items]
Class Of Warrant Or Right Warrant Redemption Terms		After the one-year anniversary of issuance, we may redeem the Tradeable Warrants for $0.01 per Tradeable Warrant if the volume weighted average price of our common stock is above $2.25 for each of 10 consecutive trading days.
Pre Funded Warrants [Member]
Schedule of Equity Method Investments [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01

Inventories, Net (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current inventories:
Raw materials	$ 4,236,912	$ 4,833,403
Work in process	1,397,524	1,891,380
Finished goods	23,627,961	23,878,040
Gross current inventories	29,262,397	30,602,823
Reserve for obsolescence	(5,223,484)	(4,336,366)
Current inventories, net	24,038,913	26,266,457
Non-current inventories:
Finished goods	1,130,980	1,385,017
Reserve for obsolescence	(413,163)	(413,163)
Non-current inventories, net	717,817	971,854
Total inventories, net	$ 24,756,730	$ 27,238,311

Property and Equipment, Net (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total cost	$ 23,022,742	$ 23,697,873
Less: accumulated depreciation	(11,571,905)	(7,857,143)
Property and equipment, net	11,450,837	15,840,730
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	4,501,118	4,629,754
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	451,177	416,233
Computer software[Member]
Property, Plant and Equipment [Line Items]
Total cost	523,526	529,726
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Total cost	214,770	181,566
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	4,030,010	4,053,837
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total cost	10,000	10,000
Surgical instruments [Member]
Property, Plant and Equipment [Line Items]
Total cost	13,292,141	13,876,757
Property and equipment, net	$ 6,700,000	$ 8,200,000

Property and Equipment, Net (Details Textual) - USD ($)	9 Months Ended
Property and Equipment, Net (Details Textual) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	$ 1,552,366
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	493,331
Depreciation	$ 3,946,352	$ 2,181,541
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Net	$ 11,450,837		$ 15,840,730
Surgical Instruments [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	$ 6,700,000		$ 8,200,000

Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
Intangible Assets (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
Accumulated amortization	$ (11,486,131)	$ (7,999,939)
Intangible assets, net	32,548,102	35,940,810
Aggregate amortization expense:	3,486,192	4,479,010
Patents [Member]
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
Gross carrying value	840,733	747,249
Technology [Member]
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
Gross carrying value	28,698,700	28,698,700
Customer relationships [Member]
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
Gross carrying value	9,911,000	9,911,000
Tradename [Member]
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
Gross carrying value	4,543,300	4,543,300
Non-compete [Member]
Finite Lived Intangible Assets Future Amortization Expense [Line Items]
Gross carrying value	$ 40,500	$ 40,500

Intangible Assets (Details 1) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Estimated amortization expense:
Remainder of 2017	$ 1,166,392
2018	4,664,156
2019	4,554,596
2020	4,471,961
2021	4,214,615
Thereafter	13,476,382
Total	$ 32,548,102	$ 35,940,810

Accrued Liabilities (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accrued Liabilities [Line Items]
Accrued stock compensation	$ 270,338	$ 213,758
Wages/commissions payable	2,467,437	3,330,578
Accrued integration expense	0	73,510
Accrued interest payable	8,194,347	3,090,585
Other accrued expenses	2,493,619	2,273,756
Accrued liabilities	$ 13,425,741	$ 8,982,187

Debt (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Loan payable to ROS and Royalty Opportunities	$ 55,787,095	$ 43,000,000
PIK Interest payable to ROS and Royalty Opportunities	10,109,062	7,648,776
6% convertible senior unsecured notes due 2021	71,865,311	70,238,166
Total	137,761,468	120,886,942
Less: debt classified as a current liability, less issuance costs	(65,609,693)	0
Less: total debt issuance costs	(1,370,563)	(1,665,508)
Long-term debt, less issuance costs	$ 70,781,212	$ 119,221,434

Debt (Details 1) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Schedule of maturities due on debt [Line Items]
Remainder of 2017	$ 0
2018	0
2019	0
2020	65,896,157
2021	71,865,311
Thereafter	0
Total	$ 137,761,468	$ 120,886,942

Debt (Details Textual) - USD ($)			1 Months Ended				3 Months Ended		4 Months Ended	9 Months Ended
Debt (Details Textual) - USD ($)	Jul. 15, 2017	Aug. 10, 2015	Oct. 31, 2017	Jan. 17, 2017	Apr. 14, 2016	Jul. 31, 2015	Dec. 31, 2017	Sep. 30, 2017	Oct. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	May 11, 2017	Dec. 31, 2016	Sep. 27, 2016	Aug. 12, 2016	Jul. 29, 2016	May 25, 2016
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 65,000,000
Conversion of Stock, Amount Converted										$ 480,000	$ 0
Business Acquisition, Percentage of Voting Interests Acquired						100.00%
Business Combination Conjunction Related Expenses						$ 4,900,000
Payments of Debt Issuance Costs						$ 4,700,000
Debt Instrument, Interest Rate Terms	to 6.00% per annum plus 100 basis points.
Debt Instrument Convertible Extent Not Convertible Beneficial Ownership Percentage								9.99%		9.99%
Interest Payable								$ 10,109,062		$ 10,109,062			$ 7,648,776
Scenario, Forecast [Member]
Debt Instrument [Line Items]
Revenues							$ 27,500,000
PIK Notes SPA [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 67,145
Debt Instrument, Convertible, Conversion Price				$ 0.7589
Debt Instrument, Maturity Date				Jul. 15, 2021
Debt Instrument, Interest Rate, Stated Percentage				6.00%
Indenture Notes SPA [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 1,560,000
Debt Instrument, Convertible, Conversion Price				$ 0.7589
Debt Instrument, Maturity Date				Jul. 15, 2021
Debt Instrument, Interest Rate, Stated Percentage				6.00%
Indenture Common Stock SPA [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued				843,289
Debt Instrument, Convertible, Conversion Price				$ 0.5692
Debt Conversion, Converted Instrument, Amount				$ 16,000,000
Xspine [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period						6.00%
Line of Credit Facility, Maximum Borrowing Capacity												$ 15,000,000
New Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Expiration Date						Jul. 31, 2020
New Facility [Member] \| First Period [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Portion Payable In Cash						9.00%
Debt Instrument Interest Rate Portion Payable In Kind						14.00%
Debt Instrument Interest Rate Addition To Pik Portion						1.00%
Debt Instrument Interest Rate Pik Portion Subtraction						9.00%
New Facility [Member] \| Second Period [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Portion Payable In Cash						12.00%
Debt Instrument Interest Rate Portion Payable In Kind						14.00%
Debt Instrument Interest Rate Addition To Pik Portion						1.00%
Debt Instrument Interest Rate Pik Portion Subtraction						12.00%
Fourth Amendment To Amended And Restated Credit Agreement [Member] \| OrbiMed and ROS [Member]
Debt Instrument [Line Items]
Debt Instrument Additional Tranche Commitment																$ 1,000,000
Debt Instrument Additional Tranche Commitment Outstanding																$ 43,000,000
Sixth Amendement To Restated New Credit Faciltiy [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Line Of Credit Facility Loans Outstanding Payment Fee Percentage														7.50%
Sixth Amendement To Restated New Credit Faciltiy [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Line Of Credit Facility Loans Outstanding Payment Fee Percentage														9.00%
Seventh Amendement To Restated New Credit Faciltiy [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from January 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate (as defined in the New Facility) for the fiscal quarter ended on December 31, 2016, or 1%.
Interest Payable	$ 1,147,329.47
Twelfth Amendement To Restated New Credit Faciltiy [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from April 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on March 31, 2017, or 1%.
Twelfth Amendement To Restated New Credit Faciltiy [Member] \| Fiscal Quarter Ended on March 31, 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis	interest accrued on such interest from April 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on March 31, 2017, or 1%.
Interest Payable	$ 1,139,597
Fifteenth Amendement To Restated New Credit Faciltiy [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from July 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%.
Sixteenth Amendment to Amended and Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from January 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate (as defined in the New Facility) for the fiscal quarter ended on December 31, 2016, or 1%.
Sixteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on March 31, 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from April 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on March 31, 2017, or 1%.
Sixteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on June 30, 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis	interest accrued on such interest from July 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%.									interest accrued on such interest from July 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%.
Interest Payable	$ 1,169,544
Seventeenth Amendment to Amended and Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Line Of Credit Facility Minimum Expected Liquidity								$ 5,000,000		$ 5,000,000
Seventeenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on March 31, 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from April 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on March 31, 2017, or 1%.
Seventeenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on December 31, 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from January 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate (as defined in the New Facility) for the fiscal quarter ended on December 31, 2016, or 1%.
Seventeenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on June 30, 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis										interest accrued on such interest from July 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%.
Amendment Number 1 to Indenture [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate Terms								to 6.00% per annum plus 100 basis points.
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 52,000,000
Debt Instrument Purchase Of Additional Notes		$ 3,000,000
Conversion of Stock, Shares Converted						257.5163
Conversion of Stock, Amount Converted						$ 1,000
Debt Instrument, Convertible, Conversion Price						$ 3.88
Term Loan [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity						$ 42,000,000
Subsequent Event [Member] \| Sixteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended On September 30, 2017 [Member]
Debt Instrument [Line Items]
Interest Payable			$ 1,482,406						$ 1,482,406
Subsequent Event [Member] \| Seventeenth Amendment to Amended and Restated Credit Agreement [Member] \| Xtant Medical Holdings and Subsidiaries [Member]
Debt Instrument [Line Items]
Line Of Credit Facility Minimum Expected Liquidity			$ 500,000						$ 500,000
Subsequent Event [Member] \| Eighteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended On September 30, 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Description of Variable Rate Basis			interest accrued on such interest from October 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%.
Silicon Valley Bank [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity																	$ 6,000,000
Silicon Valley Bank [Member] \| First Loan Modification Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity															$ 11,000,000
Convertible Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount					$ 2,238,166
Debt Instrument, Interest Rate During Period					6.00%
Conversion of Stock, Shares Converted					344.8276
Conversion of Stock, Amount Converted					$ 1,000
Debt Instrument, Convertible, Conversion Price					$ 2.90
Convertible Senior Unsecured Notes [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate Terms									to 6.00% per annum plus 100 basis points.
Convertible Promissory Notes [Member] \| PIK Notes SPA [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				2,238,166
Convertible Promissory Notes [Member] \| Indenture Notes SPA [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 52,000,000

Stock-Based Compensation (Details) - Stock Option - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Schedule of activity under stock option plans [Line Items]
Outstanding at January 1	1,205,913	664,081
Cancelled or expired, Shares	(265,958)	(105,275)
Outstanding at Sep 30	939,955	558,806
Exercisable at Sep 30	382,996	409,179
Outstanding at January 1, Weighted Average Exercise Price	$ 5.21	$ 10.64
Cancelled or expired, Weighted Average Exercise Price	3.4	9.48
Outstanding at Sep 30, Weighted Average Exercise Price	5.73	10.85
Exercisable at Sep 30, Weighted Average Exercise Price	11.44	12.67
Outstanding at January 1, Weighted Average Fair Value At Grant Date	2.82	5.32
Cancelled or expired, Weighted Average Fair Value At Grant Date	1.9	4.5
Outstanding at Sep 30, Weighted Average Fair Value At Grant Date	3.08	5.42
Exercisable at Sep 30, Weighted Average Fair Value At Grant Date	$ 5.68	$ 6.15

Stock-Based Compensation (Details Textual) - USD ($)				1 Months Ended	9 Months Ended
Stock-Based Compensation (Details Textual) - USD ($)	Jul. 25, 2017	Oct. 06, 2016	Jul. 05, 2016	Jan. 21, 2017	Sep. 30, 2017	Sep. 30, 2016	Jul. 05, 2017	Apr. 21, 2017
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares authorized under the Plan					1,900,000
Aggregate intrinsic value of options outstanding					960,000
Share-based Compensation, Total					$ 592,888	$ 522,987
President [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted		300,000
Share Price		$ 1.11
Share-based Compensation, Total					22,921
Interim Chief Executive Officer [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period				200,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted Average Exercise Price				$ 6.00
Deferred Compensation Cash-based Arrangements, Liability, Current				$ 130,000
Interim Chief Executive Officer [Member] \| First Installment [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Compensation Payable, Monthly Installments								$ 43,333
Directors and Consultants [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Allocated Share-based Compensation Expense					412,888	$ 479,888
Employee Stock Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options					$ 556,959
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price					$ 1.80
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense					$ 376,778
Restricted Stock [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options							$ 40,000
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total			130,804
Shares Issued, Price Per Share							$ 1.99
Other Noncash Expense					50,444
Restricted Stock [Member] \| Director [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period	311,688
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 240,000
Shares Issued, Price Per Share	$ 0.77
Other Noncash Expense					$ 60,000

Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
Warrants (Details) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Warrant activity [Line Items]
Outstanding	6,291,331	1,278,566
Issued	0	5,055,345
Expired	0	(42,580)
Outstanding	6,291,331	6,291,331
Outstanding Weighted Average Exercise Price	$ 2.23	$ 8.45
Issued, Weighted Average Exercise Price	0	0.9
Expired, Weighted Average Exercise Price	0	31.73
Outstanding Weighted Average Exercise Price	$ 2.23	$ 2.23

Warrants (Details 1) - $ / shares	9 Months Ended
Warrants (Details 1) - $ / shares	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Expected term	4 years 10 months 24 days	3 years 3 months
Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Value of underlying common stock (per share)	$ 0.72	$ 1.13
Risk free interest rate	1.87%	2.21%
Volatility	98.00%	79.00%
Dividend yield	0.00%	0.00%

Warrants (Details 2) - shares	9 Months Ended
Warrants (Details 2) - shares	Sep. 30, 2017	Sep. 30, 2016
Class of Warrant or Right [Line Items]
Outstanding	6,291,331	1,278,566
Outstanding	6,291,331
Warrant [Member]
Class of Warrant or Right [Line Items]
Outstanding	1,125,119	1,125,119
Derivative warrants issued, exercised and expired	0	0
Outstanding	1,125,119	1,125,119

Warrants (Details Textual)	9 Months Ended
Warrants (Details Textual)	Sep. 30, 2017 USD ($)
Class of Warrant or Right [Line Items]
Unrealized Loss On Warranty Derivative Liability	$ 136,684

Commitments and Contingencies (Details)	Sep. 30, 2017 USD ($)
Schedule of future minimum payments by operating lease [Line Items]
Remainder of 2017	$ 199,491
2018	806,747
2019	668,807
2020	396,263
2021	375,289
Thereafter	1,038,416
Total	$ 3,485,013

Commitments and Contingencies (Details 1) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Remainder of 2017	$ 123,634
2018	494,535
2019	462,544
2020	181,714
2021	0
Thereafter	0
Total minimum lease payments	1,262,427
Less amount representing interest	(285,321)
Present value of obligations under capital leases	977,106
Less current portion	(319,095)	$ (244,847)
Long-term capital lease obligations	$ 658,011	$ 832,152

Commitments and Contingencies (Details Textual) - USD ($)		9 Months Ended
	Aug. 10, 2017	Sep. 30, 2017	Sep. 30, 2016
Schedule of commitment and contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 972,283
Loss Contingency, Receivable		$ 1,342,049
Sale-leaseback Transaction for the Property Located at 664 Cruiser Lane, Belgrade, Montana [Member]
Schedule of commitment and contingencies [Line Items]
Operating Leases, Rent Expense, Net		$ 593,660	$ 661,219
Lessee Leasing Arrangements Operating Leases Term Of Each Option To Extend		5 years

Supplemental Disclosure of Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash paid during the period for:
Interest	$ 448,999	$ 4,530,170
Non-cash activity:
Issuance of capital leases	103,483	967,221
Issuance of shares associated with legal settlement	0	225,000
Interest converted into common stock	$ 480,000	$ 0

Related Party Transactions (Details Textual) - USD ($)	9 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
One Vendor [Member] \| Sales Revenue, Net [Member]
Related Party Transaction [Line Items]
Concentration Risk, Percentage	10.00%	12.00%
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	$ 5,000
American Donor Services [Member]
Related Party Transaction [Line Items]
Amount of related party transaction	$ 906,216	$ 844,643

Segment and Geographic Information (Details) - USD ($)	3 Months Ended		9 Months Ended
Segment and Geographic Information (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Total Revenue	$ 19,789,083	$ 23,094,140	$ 63,279,912	$ 65,531,879
United States [Member]
Segment Reporting Information [Line Items]
Total Revenue			61,442,431	62,253,220
Rest of world [Member]
Segment Reporting Information [Line Items]
Total Revenue			$ 1,837,481	$ 3,278,659

Segment and Geographic Information (Details Textual)	9 Months Ended
Segment and Geographic Information (Details Textual)	Sep. 30, 2017	Sep. 30, 2016
Geographic Concentration Risk [Member] \| Sales Revenue, Net [Member] \| UNITED STATES
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	97.00%	95.00%

Subsequent Events (Details Textual)			1 Months Ended				9 Months Ended
Subsequent Events (Details Textual)	Oct. 06, 2017 USD ($)	Jul. 15, 2017	Mar. 31, 2018 USD ($)	Nov. 30, 2017 USD ($)	Nov. 20, 2017 USD ($)	Oct. 31, 2017	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Subsequent Event [Line Items]
Debt Instrument, Interest Rate Terms		to 6.00% per annum plus 100 basis points.
Interest Payable							$ 10,109,062		$ 7,648,776
Depreciation, Total							$ 3,946,352	$ 2,181,541
Ninteenth Amendment to Amended and Restated Credit Agreement [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 500,000
Ninteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on December 31, 2016 [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Interest Payable				$ 1,147,329
Debt Instrument, Description of Variable Rate Basis				interest accrued on such interest from January 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on December 31, 2016, or 1%
Ninteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on March 31, 2017 [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Debt Instrument, Description of Variable Rate Basis				interest accrued on such interest from April 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on March 31, 2017, or 1%
Ninteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on March 31, 2017 [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Interest Payable				$ 1,139,597
Ninteenth Amendment to Amended and Restated Credit Agreement [Member] \| Fiscal Quarter Ended on June 30, 2017 [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Interest Payable				$ 1,303,936
Debt Instrument, Description of Variable Rate Basis				interest accrued on such interest from July 1, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%
Amendment Number 2 to Indenture [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate Terms				to 6.00% per annum plus 100 basis points.
Third Amendment and Waiver to Convertible Promissory Notes [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate Terms				to 6.00% per annum plus 100 basis points.
Subsequent Event [Member]
Subsequent Event [Line Items]
Entity Number of Employees	55
Effect on Future Earnings, Amount	$ 2,000,000
Restructuring Costs			$ 1,500,000
Subsequent Event [Member] \| Restatement Adjustment [Member]
Subsequent Event [Line Items]
Depreciation, Total					$ 618,000
Subsequent Event [Member] \| Fiscal Quarters Ended On September 30, 2017 [Member]
Subsequent Event [Line Items]
Interest Payable				$ 1,482,406
Debt Instrument, Description of Variable Rate Basis				interest accrued on such interest from October 2, 2017 until paid at a rate equal to 14% plus the higher of the LIBO Rate for the fiscal quarter ended on June 30, 2017, or 1%
Subsequent Event [Member] \| Amendment Number 2 to Indenture [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate Terms						to 6.00% per annum plus 100 basis points.
Xtant Medical Holdings and Subsidiaries [Member] \| Ninteenth Amendment to Amended and Restated Credit Agreement [Member] \| Scenario, Forecast [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 5,000,000

Inventories, Net (Details Textual) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory Current and Noncurrent Net	$ 24,756,730	$ 27,238,311
Consigned Inventory [Member]
Inventory [Line Items]
Inventory Current and Noncurrent Net	$ 12,300,000	$ 11,200,000